Monday, November 29, 2021

Reviva Pharmaceutical Holdings, Inc. (RVPH) Stock Prices Skyrocket After Success of Clinical Trial Announced

Reviva Pharmaceutical Holdings, Inc. (RVPH) stock prices were up a monumental 57.75% shortly after the trading day commenced on April 26th, 2021, bringing the price per share up to USD$6.72.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


What is RP5063?

This news came hot on the heels of the announcement of the full details for the results of RVPH’s Phase 2 clinical trial for RP5063 (brilaroxazine), its flagship drug candidate for the treatment of Acute Schizophrenia.

What does RP5063 do?


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .

Sponsored


RP5063 has the potential to modulate and stabilize the D/5-HT system on account of its novel pharmacological profile against critical dopamine and serotonin receptors. The drug has exhibited exceptional capabilities that make it a frontrunner in competing treatments because of its potent affinity and surgical selectivity for the receptors it targets, which are implicated for schizophrenia and other comorbid symptoms.

RP5063 Phase 2 Clinical Trial

The Phase 2 trial aimed to assess the safety and efficacy of the drug in a randomized, double-blind, placebo-controlled, multicenter clinical study. 234 subjects with varying degrees of acute schizophrenic or schizoaffective disorders were given either RP5063 or a placebo, with the drug having met its primary endpoint. A statistically significant reduction by 20 in the total Positive and Negative Syndrome Scale (PANSS) when comparing reports from baseline with those of the placebo indicated massive success.

Resounding Success

All safety endpoints were met by RP5063, including clinical, prolactin, fasting glucose, EKG, body weight, labs, and lipids. The drug also improved cognition and the ability to function socially, while reducing both positive and negative symptoms. Should there be a positive outcome on a relevant endpoint in the pivotal third phase of the clinical study, the U.S. Food and Drug Administration has agreed to consider a potential “Superior Safety” label claim for the drug.

Scope of RP5063

With a massive scope of 3.5 million people affected by schizophrenia in the U.S. alone, and with no existing therapies that adequately address the complexities of the disorder, RP5063 has enormous potential. The drug also lacks the host of side effects associated with current antipsychotic treatments, which the company posits could lead to a reduction in discontinuation and non-compliance rates.

Future Outlook for RVPH

The implications of the success of Phase 2 trials are not lost on investors, evidenced by the huge surge in RVPH stock prices. With such an effective treatment for a disorder with as massive an unmet need as that of schizophrenia, RP5063 could dominate the space with its medical footprint. Current and prospective investors are hopeful for this to usher in significant and sustained increases in shareholder value.

Latest news

Handle With Care: Intuit Inc. (INTU)

Intuit Inc. (NASDAQ: INTU), a manufacturer of accounting and tax computation software, has revealed its first quarter results for the fiscal year 2022. Management...

Longeveron Inc. (LGVN) stock sky rocketed during after-hours. Here’s to why?

Longeveron Inc. (NASDAQ: LGVN) stock gained by 135.27% at last close however its hiked by 50.95% in the after-hours trading session, as well. Longeveron...

Is Ford Motor Company (F) stock a better pick right now?

Ford Motor Company (NYSE: F) recently announced its third-quarter results, raised its full-year profits outlook, and resumed dividend payments. Ford has great aspirations for...

Westwater Resources, Inc. (WWR) Stock Surging in Aftermarket, Here’s Why

Westwater Resources, Inc. (WWR), an energy materials developer, has soared 19.77% in the aftermarket trading session. As a result, WWR stock is changing hands...

Related news

Handle With Care: Intuit Inc. (INTU)

Intuit Inc. (NASDAQ: INTU), a manufacturer of accounting and tax computation software, has revealed its first quarter results for the fiscal year 2022. Management...

Longeveron Inc. (LGVN) stock sky rocketed during after-hours. Here’s to why?

Longeveron Inc. (NASDAQ: LGVN) stock gained by 135.27% at last close however its hiked by 50.95% in the after-hours trading session, as well. Longeveron...

Is Ford Motor Company (F) stock a better pick right now?

Ford Motor Company (NYSE: F) recently announced its third-quarter results, raised its full-year profits outlook, and resumed dividend payments. Ford has great aspirations for...

Westwater Resources, Inc. (WWR) Stock Surging in Aftermarket, Here’s Why

Westwater Resources, Inc. (WWR), an energy materials developer, has soared 19.77% in the aftermarket trading session. As a result, WWR stock is changing hands...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

1745

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam